Pooled BROADWAY & BROOKLYN Analyses

Name: Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
Uploaded: 2025-09-02T04:00:00+00:00
Description: This program is intended for health care professionals only. Dr. Ray r

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

CETP Inhibition and Obicetrapib: A New Era in Lipid Management
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
Hyperlipidemia
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
- Kausik Ray, MBChB, MD, MPhil
Plozasiran improves QoL in patients with FCS
Plozasiran improves QoL in patients with FCS
EAS 2025
Plozasiran improves QoL in patients with FCS
- Gerald Watts, MD, PhD
The Road Ahead: What's on the Horizon for FCS and SHTG Management
The Road Ahead: What's on the Horizon for FCS and SHTG Management
MinuteCE®
The Road Ahead: What's on the Horizon for FCS and SHTG Management
1.00 program credit
- Pam R. Taub, MD, FACC, FASPC
- Prof. Kausik Ray
1.00 program credit
SHTG: Decoding the Latest Clinical Trial Outcomes
SHTG: Decoding the Latest Clinical Trial Outcomes
MinuteCE®
SHTG: Decoding the Latest Clinical Trial Outcomes
1.00 program credit
- Pam R. Taub, MD, FACC, FASPC
- Kausik Ray, MBChB, MD, MPhil
1.00 program credit

Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses

Recommended

Title

Share on ReachMD